Zolbetuximab | Search results

Showing 1 to 3 of 3 results for zolbetuximab

Sort by

Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (TA1046)
Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.
Result type
Technology appraisal guidance
Published
12 March 2025
View recommendations for TA1046
Show all sections
Sections for TA1046
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040]
Awaiting development Reference number: GID-TA11591 Expected publication date: TBC
Result type
Technology appraisal guidance
Status
Awaiting development
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]
In development Reference number: GID-TA11560 Expected publication date: TBC
Result type
Technology appraisal guidance
Status
In development